M&A
confidence high
sentiment positive
materiality 0.65
Stereotaxis completes acquisition of Robocath for ~$20M in cash and stock
Stereotaxis, Inc.
- Deal valued at ~$20M in cash and common stock; earnout up to $25M based on regulatory/commercial milestones.
- Issued 1,469,485 shares and 4,575,143 pre-funded warrants to Robocath shareholders at closing.
- Robocath fully integrated into Stereotaxis, combining robotic platforms for electrophysiology, interventional cardiology, and neurointerventions.
- Earnout consideration may be paid in cash or stock at Stereotaxis' election, capped at 19.9% of outstanding shares without stockholder approval.
- Transaction closed July 7, 2026; resale registration statement for stock consideration to be filed.